Global Newcastle Disease Vaccine Market - 2022-2029

Global Newcastle Disease Vaccine Market - 2022-2029

Market Overview

Newcastle Disease Vaccine Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 3.6 % during the forecast period (2022-2029).

Newcastle disease is a contagious disease of birds that affects many avian species, both wild and domestic animals, and it is transmissible to humans. Several Newcastle disease vaccines available in the global market are appropriate for commercial chickens. The I-2 Newcastle disease vaccine, a thermostable vaccine, has been manufactured for local or regional development and tackles Newcastle disease in village chickens. After storage for 1-2 hours at room temperature, numerous Newcastle disease vaccinations deteriorate. It renders them unsuitable for use in villages where the vaccine must be transferred at room temperature for hours or days. Raising vaccines to limit outbreaks of avian disease and the increasing demand for food items related to poultry drive the global market's growth. The growing awareness drives the market among veterinary practitioners of animal vaccination, rising government food safety initiatives, and increasing meat consumption.

Market Dynamics: Rising R&D for the new vaccine by market players leads the market’s growth.

One of the major factors augmenting the market's growth includes the number of new veterinary vaccines introduced by animal companies. Besides, increasing pipeline products that will enter the future further contribute to market growth. For instance, in May 2022, the Newcastle disease virus-based trivalent vaccine was effective across SARS-CoV-2 variants in mice. The present study findings demonstrated that its trivalent formulation, composed of the ancestral Wuhan, Delta, and Beta NDV-HXP-S variants, induced substantially high levels of cross-neutralizing antibodies against the phylogenetically distant SARS-CoV-2 variants, including Omicron.

Also, growth in emerging economies during the forecast period drives market growth. China's increasing demand for meat makes it one of the largest markets for animal healthcare products for livestock animals. According to the National Bureau of Statistics of China, pork production in China was up 28.8% year-on-year in 2021. China's total meat production is 52.96 million tons in the year 2021. Moreover, the diseases that affect livestock pose a devastating impact on animals' productivity and food products such as meat and other animal products. The initiative aims to reduce smallholder farmers' annual losses in Africa from Newcastle disease of poultry and endoparasites and East Coast fever and Foot-and-mouth disease by providing access to prevent such diseases.

Market Segmentation: Thermostable vaccine segment accounted for the highest share in global newcastle disease vaccine market.

The thermostable vaccine is expected to project the highest CAGR in the Newcastle disease vaccine market during the forecast period. This significant growth is due to its resistance to inactivation on exposure to high temperatures. Thermostable Newcastle disease virus (NDV) vaccines are used extensively to protect village chickens against Newcastle disease, backed by their decreased dependence on the cold chain for transport and storage. Though, the genetic basis underlying NDV thermostability is poorly understood.

By application, the newcastle disease vaccine market is classified into chicken, turkey, and others. A chicken segment held a significant role in the global Newcastle disease vaccine market during the forecast period. Chickens are susceptible to various infectious diseases. The viral disease known as Newcastle disease causes catastrophic losses to both village and commercial chickens and is among the most significant diseases that occur to chickens. Reducing large numbers of village chickens to Newcastle's contagious disease is a major first step in enhancing their productivity, driving the need for Newcastle disease vaccine chickens.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American market leads with the largest market share in the global Newcastle disease vaccine market during the forecast period. Increased consumption of poultry-related food items, a high incidence of avian diseases, and consumer perception of food safety are some factors driving the market growth in the region, especially in the U.S. Moreover, poultry meat's thriving production has played a crucial role in the region's dominance in the market. According to the United Nations Food and Agriculture Organization (UNFAO), the U.S. is the largest producer of poultry meat globally; accounting For 2020, the number of all chickens in the United States totaled around 518.3 million. Furthermore, the country's adoption of poultry vaccines is being driven by joint strategic projects and acquisitions to foster better avian health further.

Moreover, the Asia Pacific region is expected to project the highest CAGR globally during the forecast period. The growing awareness of poultry vaccines coupled with the increase in the number of vaccination awareness programs in the region is some factors that are expected to offer growth opportunities to the market during the forecast period.

Competitive Landscape:

The Newcastle disease vaccine market is dominated by a few companies. Some of the key players in the market's growth include Boehringer Ingelheim, Ceva Animal Health LLC, CAVAC, GALVmed, Hester Biosciences Limited, Merck Animal Health, Elanco, Zoetis, Inc., and QYH Biotech, among others. The key players execute several growth strategies, such as product launches, acquisitions, and collaborations, which are estimated to boost the Newcastle disease vaccine market growth globally. Some major key players launched new vaccines in the market to protect animals from various diseases. For instance, in January 2020, Boehringer Ingelheim launched a vaccine named VAXXITEK HVT+IBD+ND to protect poultry from the diseases like Marek's Disease, Infectious Bursal Disease (classic and variant types) and Newcastle Disease. The Company manufactured this vaccine at its manufacturing site in Georgia, which produced more than 60 billion doses of poultry vaccine a year for use in the United States and over 60 other countries. In June 2022, Ceva Santé acquired Canadian Firm Artemis Technologies, Inc. to expand its oral rabies vaccine portfolio. Through this acquisition, Ceva expands its presence in North America. In April 2020, the Indian Institute of Technology Guwahati and Hester Biosciences collaborated to develop a new vaccine against coronavirus (COVID-19). This vaccine is based on a recombinant avian paramyxovirus vector platform.

COVID-19 Impact: Negative impact on the global newcastle disease vaccine market.

The outbreak of COVID-19 has certainly impacted the global Newcastle disease vaccine market. The lockdown has compelled the veterinaries to close their operations, or even if the vets are open, the public was afraid to visit vets for vaccination in the meantime. Therefore, the Newcastle disease vaccine market significantly declined in 2020. Stringent regulations after the COVID-19 pandemic regarding the vaccinations of animals to prevent disease spread are expected to propel market growth in the next couple of years.